Compare Amgen, Inc. (AMGN) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Okta, Inc. — how do they compare? Amgen, Inc. trades at $356.92 (market cap $196.12B), while Okta, Inc. trades at $139.52 (market cap $24.09B). The key difference: Amgen, Inc. is far larger — about 8.1× Okta, Inc.'s market cap, and Amgen, Inc. pays a 2.77% dividend while Okta, Inc. pays none. Which is the better fit depends on your goals.
| AMGN | OKTA | |
|---|---|---|
Market Cap | $196.12B | $24.09B |
Sector | Health | Technology |
52-Week High | $388.16 | $148.84 |
52-Week Low | $271.18 | $62.93 |
Enterprise Value | $241.41B | $21.92B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
OKTA trades at $138.63, down 6.86% today, but maintains strong technical momentum with bullish moving averages and recent AI-driven demand boosting cybersecurity stocks. The company shows improving fundamentals with revenue growth to $2.61B in 2025 and three consecutive quarterly EPS beats. Positive sentiment is driven by AI security adoption and institutional interest, though high valuations (P/E 100.46) and overbought RSI levels warrant caution.
Outlook remains positive with AI security demand accelerating revenue growth and improving profitability (2026 net margin projected at 8.24%). Key risks include intense cybersecurity competition and valuation concerns. Analyst consensus is strongly bullish (73% buy ratings) with $124.08 price target, though current price exceeds consensus suggesting near-term consolidation potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
